On April 18, 2020 MOMA Therapeutics reported that it has launched with $86 million in series A financing, led by Third Rock Ventures, to develop small-molecule drugs against a family of more than 400 proteins—MOMA calls them molecular machines—that use ATP hydrolysis to "generate force and motion (Press release, MOMA Therapeutics, APR 18, 2020, View Source,DNA%20helicases%20and%20chromatin%20remodeling [SID1234561265])." Examples include DNA helicases and chromatin remodeling proteins, which regulate gene expression. The company has recruited experts in protein biophysics and cryogenic electron microscopy to target molecular machines implicated in cancer and rare diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!